Point Therapeutics Presents Talabostat's Novel Dual Mechanism of Action During Research and Development DayTalabostat's dual me

Point Therapeutics, Inc. (NASDAQ:POTP) presented
preclinical data further elucidating talabostat's novel dual mechanism
of action during a Company Research and Development Day on April 25,
2006 in New York City. Talabostat is a targeted agent that inhibits
dipeptidyl peptidases (DPPs), which are enzymes that regulate
biological processes, including tumor growth and immune responses. As
a stromal targeted agent, talabostat inhibits fibroblast activation
protein (FAP), a DPP that has been shown to contribute to tumor
growth. Yesterday, the company also announced that talabostat targets
DPP 8 and DPP 9, which have been demonstrated to enhance immune
functions in preclinical studies. Talabostat's novel dual mechanism of
action introduces a potential new approach for the treatment of
cancer.

   FAP is expressed in the stroma, or connective tissue, of more than
90 percent of epithelial carcinomas, including non-small cell lung,
pancreatic, colorectal, ovarian and breast cancers as well as melanoma
and some bone and soft tissue sarcomas. Peer-reviewed data from the
Fox Chase Cancer Center suggest that talabostat, a high affinity
inhibitor of FAP, can suppress tumor growth via FAP inhibition in
mouse models.

   New preclinical data presented at yesterday's R&D Day show that
talabostat's inhibition of two other important DPPs, DPP 8 and DPP 9,
may enhance immune functions and promote the body's natural ability to
fight cancer. The preclinical data demonstrate that DPP 8 and DPP 9
inhibition may cause the activation of caspase-1 which leads to an
increase in a key cytokine, interleukin-1beta (IL-1beta). By its
ability to activate caspase-1 with the resultant induction of
IL-1beta), talabostat can stimulate the production of cytokines and
chemokines that are known to promote anti-tumor responses by both the
innate branch of the immune system involving neutrophils, macrophages
and natural killer cells, and the adaptive branch involving
tumor-specific T lymphocytes. Collectively, cytokines and chemokines
maintain and regulate the function of the immune system.

   "These proof of concept data are important because they validate a
preclinical mechanism that is quite unique in oncology. The very
nature of talabostat's dual mechanism of action speaks to its
potential versatility as a targeted agent with broad utility in
several different cancers," said Dr. Charles Dinarello. Dr. Dinarello
is a Professor of Medicine at the University of Colorado School of
Medicine. An expert on IL-1, Dr. Dinarello also serves on the
Company's Scientific Advisory Board.

   "We are very excited by these data because they speak to the
potential efficacy of inhibiting key DPPs to treat cancer--a novel
approach to treating the disease," said Dr. Barry Jones, Senior Vice
President and Chief Scientific Officer at Point Therapeutics. "To my
knowledge, talabostat is the first DPP inhibitor being developed for
the treatment of cancer. To date, talabostat has been studied in more
than 500 people, including two ongoing Phase 3 studies for non-small
cell lung cancer and Phase 2 studies for chronic lymphoid leukemia,
metastatic melanoma, and pancreatic cancer."

   A replay of the company's Web cast and copies of the presentation
can be downloaded on the corporate Web site, www.pther.com

   About Point Therapeutics, Inc.:

   Point is a Boston-based biopharmaceutical company developing a
portfolio of dipeptidyl peptidase (DPP) inhibitors for use in cancer,
type 2 diabetes and as vaccine adjuvants. Point is currently studying
its lead product candidate, talabostat, in two Phase 3 trials in
non-small cell lung cancer. Point is also studying talabostat in
several Phase 2 trials, including as a single-agent in metastatic
melanoma, in combination with cisplatin in metastatic melanoma, in
combination with rituximab in advanced chronic lymphocytic leukemia,
and in combination with gemcitabine in metastatic pancreatic cancer.
In addition, Point's portfolio includes two other DPP inhibitors in
preclinical development--PT-630 for type 2 diabetes, and PT-510 as a
vaccine adjuvant.

   Certain statements contained herein are not strictly historical
and are "forward looking" statements as defined in the Private
Securities Litigation Reform Act of 1995. This information includes
statements with respect to the company's clinical development programs
and the timing of initiation and completion of its clinical trials.
Forward-looking statements are statements that are not historical
facts, and can be identified by, among other things, the use of
forward-looking language, such as "believes," "feels," "expects,"
"may," "will," "should," "seeks," "plans," "schedule to,"
"anticipates" or "intends" or the negative of those terms, or other
variations of those terms of comparable language, or by discussions of
strategy or intentions. A number of important factors could cause
actual results to differ materially from those projected or suggested
in the forward looking statement, including the risk factors described
in Point's annual report on Form 10-K for the year ended December 31,
2005 and from time to time in Point's periodic and other reports filed
with the Securities and Exchange Commission.